WinstonWınston
Stemtech Corporation logo

Stemtech Corporation

STEK
Drug Manufacturers - Specialty & Generic · Healthcare
Price
$0.00
+0.00 (+0.00%)
Market Cap
$14,618
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+351.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 37.6M (2021) → 169.8M (2025)

Stemtech Corporation is a small health and wellness company that sells nutritional supplements. Its products are designed to support the body's natural stem cells — the cells that help repair and renew tissues. Stemtech sells directly to consumers, often through a network of independent distributors, and markets its products mainly to adults interested in anti-aging and general wellness.

The company earns money by selling its supplement products, primarily through a direct sales or multi-level marketing model. Stemtech operates in multiple countries, though it remains a very small company with a market cap near zero. Its high gross margin suggests low production costs relative to selling prices, but the deeply negative operating margin means it is spending far more than it earns, raising serious concerns about long-term financial sustainability. The biggest risk the company faces is proving that its products deliver measurable health benefits in a crowded supplement market where scientific credibility and regulatory scrutiny are growing.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-17.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+44.3% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

29.5%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$255,416 cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Stemtech Corporation's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
80.1%
Premium pricing power — 80.1% gross margin
Operating Margin
-39.8%
Losing money on operations — -39.8%
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-26.8%
Shrinking sales (-26.8% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-43.7%
Burning cash (-43.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial